Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Files For Approval Of Rasilez In Japan

This article was originally published in PharmAsia News

Executive Summary

Novartis Pharma of Japan has applied for approval of the high blood pressure drug Rasilez (aliskiren). Aliskiren is the first in a new class of medicine that works by inhibiting renin (an enzyme secreted by the kidney). Aliskirenhas been approved by the U.S. FDA and is sold under the name Tektuna in the U.S. and as Rasilez in Europe. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067898

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel